Boston Scientific's Rezūm system effective out to five years in benign prostatic hyperplasia: study

Study data published in the Journal of Urology showed that Boston Scientific's Rezūm water vapour therapy provided men with benign prostatic hyperplasia (BPH) "significant, sustained" symptom relief and quality of life improvements for five years. Principal investigator Kevin McVary remarked that "these new five-year results expand upon the growing clinical evidence supporting the long-term durability of the Rezūm system as the leading minimally invasive option for men facing moderate-to-severe BPH-related symptoms."

The company announced last year that the system had provided durable results and preserved sexual function four years after treatment. The latest results show that the respective surgical retreatment and medication rates were 4.4% and 11.1% at the end of the five-year trial. Meanwhile, patients' International Prostate Symptom Score (IPSS), peak urinary flow rate and quality of life were all significantly improved versus baseline, at 48%, 49% and 49% respectively.

According to Boston Scientific, the Rezūm system reduces adenoma tissue with water vapour through a minimally invasive procedure, allowing cell remnants to be absorbed by the body. The procedure is typically performed during a single physician's office visit and does not require general anaesthesia or surgical implants. The system received the CE mark in 2013 and FDA 510(k) clearance in 2015.

Boston Scientific gained the Rezūm system through its acquisition of NxThera, which closed in 2018.

Did you like this article?